[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338171-105":59,"doc-detail-338171-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","systematic-review-of-economic-evaluations-of-systemic-treatments-for-advanced-and-metastatic-gastric-cancer","Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer","","Recent advances in biomarker-directed therapy and immunotherapy may improve survival and quality of life for advanced and metastatic gastric cancer, but decision makers face uncertainty about relative effectiveness, high costs, and cost effectiveness. This review identifies economic evaluations for second-line or later-line systemic treatments and evaluates key model criteria, reporting completeness, and methodological quality. A systematic search to 5 March 2023 focused on cost-effectiveness and cost-of-illness studies with CHEERS and Philips Checklist assessments.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/systematic-review-of-economic-evaluations-of-systemic-treatments-for-advanced-and-metastatic-gastric-cancer/338171/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/systematic-review-of-economic-evaluations-of-systemic-treatments-for-advanced-and-metastatic-gastric-cancer/338171.png","ImageObject",300,407,{"name":92,"@type":93},"Levi","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main objective of this systematic review?","Question",{"text":112,"@type":113},"To identify economic evaluations for second-line or later-line treatment of advanced and metastatic gastric cancer, and to assess key criteria, reporting completeness, and methodological quality.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which types of economic studies were included and how were they synthesized?",{"text":117,"@type":113},"Nineteen eligible evaluations were identified, comprising 15 cost-effectiveness studies and 4 cost-of-illness studies. A narrative synthesis focused on cost-effectiveness and cost-of-illness outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings about cost effectiveness and reporting quality?",{"text":121,"@type":113},"Most interventions were more effective and more costly than comparators, but most were not cost effective. There was also a general lack of consistency across studies, and no studies fully met reporting completeness and methodological-quality requirements.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338171,1790809418,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},7971461740909,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","PharmacoEconomics (2024) 42:1091–1110  \n[https://doi.org/10.1007/s40273-024-01413-8](https://doi.org/10.1007/s40273-024-01413-8)  \nSystematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer  \nShikha Sharma1,2 · Niamh Carey2,3 · David McConnell2,3 · Maeve Lowery4 · Jacintha O’Sullivan4 · Laura McCullagh2,3 · for the HEALED Consortium  \nAccepted: 2 July 2024 / Published online: 26 July 2024 © The Author(s) 2024  \nAbstract  \nBackground Recent advances in the development of biomarker-directed therapy and immunotherapy, for advanced and metastatic gastric cancers, have the potential to improve survival and quality of life. Much attention has been directed towards second-and later-line treatments, and the landscape here is evolving rapidly. However, uncertainty in relative effectiveness, high costs and uncertainty in cost effectiveness represent challenges for decision makers.  \nObjective To identify economic evaluations for the second-line or later-line treatment of advanced and metastatic gastric cancer. Also, to assess key criteria (including model assumptions, inputs and outcomes), reporting completeness and methodological quality to inform future cost-effectiveness evaluations.  \nMethods A systematic literature search (from database inception to 5 March 2023) of EconLit via EBSCOhost, Cochrane Library (restricted to National Health Service [NHS] Economic Evaluation Database and Health Technology Assessment [HTA] Database), Embase, MEDLINE and of grey literature was conducted. This aimed to identify systemic treatments that align with National Comprehensive Cancer Network (NCCN) and European Society for Medical Oncology (ESMO) Clinical Practice Guidelines. Data were collected on key criteria and on reporting completeness and methodological quality. A narrative synthesis focussed on cost-effectiveness and cost-of-illness studies. Outcomes of interest included total and incremental costs and outcomes (life-years and quality-adjusted life-years), ratios of incremental costs per unit outcome and other summary cost and outcome measures. Also, for cost-effectiveness studies, reporting completeness and the methodological quality were assessed using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) and the Philips Checklist, respectively.  \nResults A total of 19 eligible economic evaluations were identified (cost-effectiveness studies [n = 15] and cost-of-illness studies [n = 4]). There was a general lack of consistency in the methodological approaches taken across studies. In the main, the cost-effectiveness studies indicated that the intervention under consideration was more effective and more costly than the comparator(s) . However, most interventions were not cost effective. No studies were fully compliant with reportingcompleteness and methodological-quality requirements. Given the lack of consistency in the approaches taken across costof-illness studies, outcomes could not be directly compared.  \nConclusions To our knowledge, this is the first published systematic literature review that has qualitatively synthesised economic evaluations for advanced and metastatic gastric cancer. There were differences in the approaches taken across the cost-effectiveness studies and the cost-of-illness studies. The conclusions of most of the cost-effectiveness studies were consistent despite identified differences in approaches. In the main, the interventions under consideration were not cost effective, presenting challenges to sustainability and affordability. We highlight a requirement for cost-effectiveness evaluations and for second-line or later-line treatments of advanced and metastatic gastric cancer that consider all relevant comparators and that are compliant with reporting-completeness and methodological-quality requirements. By addressing the methodological gaps identified here, future healthcare decision-making, within the context of this rapidly changing treatmen","cbCainPtBlQptn72","https://ap.wps.com/l/cbCainPtBlQptn72","pdf",1875128,"English","# Abstract\n# Background\n# Objective\n# Methods\n# Results\n# Conclusions\n# Key Points for Decision Makers\n# Introduction","[{\"question\":\"What is the main objective of this systematic review?\",\"answer\":\"To identify economic evaluations for second-line or later-line treatment of advanced and metastatic gastric cancer, and to assess key criteria, reporting completeness, and methodological quality.\"},{\"question\":\"Which types of economic studies were included and how were they synthesized?\",\"answer\":\"Nineteen eligible evaluations were identified, comprising 15 cost-effectiveness studies and 4 cost-of-illness studies. A narrative synthesis focused on cost-effectiveness and cost-of-illness outcomes.\"},{\"question\":\"What were the key findings about cost effectiveness and reporting quality?\",\"answer\":\"Most interventions were more effective and more costly than comparators, but most were not cost effective. There was also a general lack of consistency across studies, and no studies fully met reporting completeness and methodological-quality requirements.\"}]","Systematic Review of Economic Evaluations of Systemic Treatments for Advanced and Metastatic Gastric Cancer | PDF",1790022335,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cba768dcc1f5144b07d8d1752fb72df1.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a5f31cec5005bdbf9065ab7044ce4205.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76cc07b0193636a2df08b43043fdb9b8.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/03267d786d972c9ed0d86f51d8106429.webp",980,1301]